Results 261 to 270 of about 81,856 (291)

Pramipexole augmentation in treatment-resistant major depressive disorder

Expert Review of Neurotherapeutics, 2013
Evaluation of: Cusin C, Iovieno N, Iosifescu DV et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J. Clin. Psychiatry 74(7), e636-e641 (2013). To overcome limited efficacy in antidepressants, clinicians may choose augmentation, switching to a different ...
openaire   +2 more sources

The ‘Dalhousie Serotonin cocktail’ for treatment-resistant major depressive disorder

Journal of Psychopharmacology, 2001
We describe the successful treatment of five patients with treatment-resistant major depressive disorder (TR-MDD) with a combination pharmacotherapy of pindolol, tryptophan and nefazodone. Five TR-MDD outpatients who had previously not responded to at least four different antidepressant medication trials were initiated on 300 mg/day of nefazodone, 7.5
S M, Dursun, S, Devarajan, S, Kutcher
openaire   +2 more sources

Mismatch negativity in treatment-resistant depression and borderline personality disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010
Cognitive dysfunctions, such as attentional impairment, are central features of both treatment-resistant depression (TRD) and borderline personality disorder (BPD). The treatment failure of TRD due to its comorbidity with BPD is debated in the literature.
Wei, He, Hao, Chai, Leilei, Zheng, Wenjun, Yu, Wanzhen, Chen, Jianming, Li, Wei, Chen, Wei, Wang   +7 more
openaire   +2 more sources

Use of atypical antipsychotics for treatment-resistant major depressive disorder

Current Psychiatry Reports, 2008
Despite the progressive increase in the number of pharmacologic agents with potential antidepressant activity, many patients suffering from major depressive disorder (MDD) continue to be symptomatic. Clearly, an urgent need exists to develop safer, better tolerated, and more effective treatments for MDD.
George I, Papakostas, Richard C, Shelton
openaire   +2 more sources

Moderate exercise improves depression parameters in treatment-resistant patients with major depressive disorder

Journal of Psychiatric Research, 2011
Treatment-resistant major depressive disorder (MDD) is a complex condition, with very low remission rates. Physical exercise has been used, with some encouraging results, as an alternative therapy in other depressive disorders. This study assessed the impact on depression and functioning parameters of a moderate intensity exercise program, as an ...
Mota-Pereira, Jorge, Silvério, Jorge Manuel Amaral, Carvalho, Serafim, Ribeiro, José Carlos, Fonte, Daniela, Ramos, Joaquim   +5 more
openaire   +3 more sources

Hypothalamo-Pituitary-Adrenal Axis in Depressive Disorders and Treatment Resistance

Psikhiatriya, 2023
Background: hypothalamo-pituitary-adrenal (HPA) axis plays an important role in the pathogenesis of depression. Patterns of HPA functioning depend on both biologic factors and psychological background, which, taken together, may increase the risk of depression later on.
O. A. Yunilayne, E. G. Starostina, I. V. Oleichik   +2 more
openaire   +1 more source

Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009
We examined the efficacy and tolerability of perospirone, a dopamine D2 and 5-HT2A receptor antagonist and a partial 5-HT1A receptor agonist, in the augmentation of antidepressant treatment of partially responding and nonresponding patients with major depressive disorder.
Yasushi, Sato, Norio, Yasui-Furukori, Taku, Nakagami, Manabu, Saito, Sunao, Kaneko   +4 more
openaire   +2 more sources

Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders

2016
Since the first report of a robust antidepressant effect of a sub-anesthetic dose of ketamine in 2000, studies have repeatedly confirmed its therapeutic benefits in major depressive disorder (MDD) as well as in depressive episodes in patients with bipolar disorder (BD). Two features of the antidepressant response to ketamine make it striking: first, it
Pierre Blier, Jean Blier
openaire   +1 more source

Treatment-resistant major depressive disorder and assisted dying: response to comments

Journal of Medical Ethics, 2015
The commentaries responding to our article on treatment-resistant depression and assisted dying focus on the following issues: epistemological questions about death, patient competence, the role of doctors, the moral basis of the right to an assisted death, safety and security of patients, and questions about various cases that occurred in the ...
Schuklenk, Udo, van de Vathorst, Suzanne
openaire   +3 more sources

Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder

Current Medical Research and Opinion, 2010
Treatment-resistant depression (TRD) imposes substantial cost from the perspective of employers. The objective of this study was to assess direct healthcare costs and indirect (disability and medical-related absenteeism) costs associated with TRD compared with non-treatment-resistant major depressive disorder (MDD).Employees with one or more inpatient,
Jasmina I, Ivanova, Howard G, Birnbaum, Yohanne, Kidolezi, Ganesh, Subramanian, Sajjad A, Khan, Michael D, Stensland   +5 more
openaire   +2 more sources